MPLT: Raymond James Initiates
Raymond James initiates coverage on MapLight Therapeutics with a Strong Buy rating and a price target of $46
Raymond James analyst Tiago Fauth initiates coverage on MapLight Therapeutics (NASDAQ: MPLT ) with a Strong Buy rating and announces Price Target of $46.